tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Leah Rush Cann, 92 are a BUY (97.87%), 2 are a HOLD (2.13%).
Analyst Leah Rush Cann, currently employed at BROOKLINE, carries an average stock price target met ratio of 52.75% that have a potential upside of 42.44% achieved within 344 days. Previously, Leah Rush Cann worked at OPPENHEIMER, CANACCORD.
Leah Rush Cann’s has documented 229 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on KYMR, Kymera Therapeutics at 07-Jul-2025.
Analyst best performing recommendations are on SYRS (SYROS PHARMACEUTICALS).
The best stock recommendation documented was for MRNA (MODERNA) at 11/25/2020. The price target of $164 was fulfilled within 13 days with a profit of $54.82 (50.21%) receiving and performance score of 38.62.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 09-Jan-2025
$435
$-2.23 (-0.51%)
$400
Buy Since 01-Jan-2025
$457
$19.77 (4.52%)
$427
Buy Since 05-Feb-2023
$460
$22.77 (5.21%)
$400
Hold Since 22-Aug-2019
$352
$-85.23 (-19.49%)
$303
Hold Since 06-Oct-2024
$400
$-37.23 (-8.51%)
$350
What Year was the first public recommendation made by Leah Rush Cann?
